Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies.
about
Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopesProduction of Furin-Cleaved Papillomavirus Pseudovirions and Their Use for In Vitro Neutralization Assays of L1- or L2-Specific AntibodiesControl of HPV-associated tumors by innovative therapeutic HPV DNA vaccine in the absence of CD4+ T cells.Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 InfectionImmunoprevention of human papillomavirus-associated malignanciesSeroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal AntibodiesImmunologic Control of Mus musculus Papillomavirus Type 1.Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated diseaseProgress and prospects for L2-based human papillomavirus vaccinesFurin Cleavage of L2 during Papillomavirus Infection: Minimal Dependence on Cyclophilinsα-Defensin HD5 Inhibits Human Papillomavirus 16 Infection via Capsid Stabilization and Redirection to the LysosomeDevelopments in L2-based human papillomavirus (HPV) vaccines.Extracellular conformational changes in the capsid of human papillomaviruses contribute to asynchronous uptake into host cells.Roles of Fc domain and exudation in L2 antibody-mediated protection against human papillomavirus.
P2860
Q28603888-371C777A-A642-490D-A7C3-62C1937598D7Q28611356-207711B8-2696-4E81-9E28-105F5A670E4AQ33589738-0756C846-1549-47EF-8ACD-3171FECA3773Q33856453-7D915070-1774-4D87-B891-39514C6FAC94Q33907700-1A1770A1-2632-484F-9F2B-6F8D2F6F9B65Q35044376-6748AEEB-B339-4B17-ADD3-896AF41D4E6FQ35773930-426923BF-A3BE-4EAE-9A44-72FC5F98F67DQ35818624-FCF6AFBD-D221-4D0A-AF8B-513635222A0FQ36616505-44D0B7A8-E3FC-48BF-9700-2D02F26AFEA5Q37014047-430D0691-6CC2-471F-8DC6-88581FD349F8Q37073350-ADFDAF93-D81E-4AAB-9BEF-6D3771AC5911Q38719590-FD4585D4-D0E8-4CC0-8005-EBCD7B415833Q39021001-ADB39648-8796-41D9-AAA0-5B860FF97181Q52625020-902AA4F9-E0BE-4430-A574-B688A5E22D55Q54216752-9BEFFF6A-C01F-451D-A8A4-F4DFF6615E2E
P2860
Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Preparation and properties of ...... ty for neutralization studies.
@en
Preparation and properties of ...... ty for neutralization studies.
@nl
type
label
Preparation and properties of ...... ty for neutralization studies.
@en
Preparation and properties of ...... ty for neutralization studies.
@nl
prefLabel
Preparation and properties of ...... ty for neutralization studies.
@en
Preparation and properties of ...... ty for neutralization studies.
@nl
P2093
P2860
P1433
P1476
Preparation and properties of ...... ty for neutralization studies.
@en
P2093
Chenguang Wang
Joshua W Wang
Kihyuck Kwak
Reinhard Kirnbauer
Richard B S Roden
Shiwen Peng
Subhashini Jagu
P2860
P304
P356
10.1016/J.VIROL.2013.10.038
P407
P577
2013-12-20T00:00:00Z